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Psychiatrists' attitudes towards outcomes from schizophrenia are lacking in ‘hope’; this 
is not only demoralizing for patients and their families but limits the extent to which 
psychiatrists utilize the interventions that hold promise for improving outcomes – using 
clozapine, long-acting injectable antipsychotic medications (LAIs) and psychosocial 
interventions. This seems a controversial statement that most psychiatrists would disagree 
with, however the experience of mental health users is that professionals often have a negative 
perspective of schizophrenia that they suggest directly affects them, making them less hopeful1. 
This lack of hope is evidenced by the failure to offer these treatment options to patients, thus, 
denying patients the potential benefits of these treatments and indeed contributes to a self-
fulfilling prophecy of poor outcomes. Here we examine the basis of this biased view of 
outcomes in schizophrenia, that directly influence psychiatrists’ own ‘hope’ towards the 
prognosis and impacts on their decisions concerning pharmacological and psychological 
therapy. We also discuss the impact of ‘hype’ related to new discoveries in the field, which in 
the long term may have a deleterious effect on treatment.  
 
What is hope? In the medical literature the term ‘hope’ is frequently cited as a 
fundamental element for a successful treatment 1, 2. Hope has many definitions including a 
positive perspective of the future; the expectation of achieving an objective; an effective coping 
strategy; an inner power that enables one to overcome obstacles (for review see 3). As 
originally theorized by Snyder et al.3, the ‘hope theory’ refers to an individual’s positive 
perspective that make them invest energy and planning toward goal attainment. Hope is often 
confused with optimism; optimism or ‘hype’ is related to the individual’s general expectancy for 
good rather than bad outcomes in their life. The hope theory intends to assess one’s capacity to 
select appropriate routes and overcome barriers to goals rather than just one’s confidence in a 
positive outcome. This can best be exemplified by the following analogy – an optimistic person 
would expect no rain and therefore leave home without an umbrella, while the hopeful person 
would expect no rain but take an umbrella to cope with any unexpected rain. How can one 
evidence the importance of hope? One could examine data from diseases where it is possible to 
have biological measures of outcomes – an example would be diabetes mellitus. Van Allen et 
al.2 prospectively examined the associations between patients’ hope and optimism with health 
outcomes in a sample of young people with Type 1 diabetes mellitus; they found that hope 
improved glycaemic control while optimism did not help – they suggest interventions that could 
be used to improve patients’ hope.  
Although hope is a key element for recovery 1, how many psychiatrists have a truly 
positive perspective of outcomes in schizophrenia? Schizophrenia has traditionally been viewed 
as a neurodegenerative chronic condition with a very pessimistic outlook. The tautological 
approach in which the diagnosis of schizophrenia is questioned when there is complete return 
to premorbid functioning still prevails. Perhaps it is not surprising that psychiatrists display 
higher scores of negative stereotypes of schizophrenia and perceived prejudice than the 
general population 4. 
So why is it that clinicians still have a negative perspective of schizophrenia? According 
to Cohen and Cohen 5, psychiatrists suffer from ‘the clinician’s illusion’ – since the patient 
population who seek specialized treatment are chronic, more severe and have more 
comorbidities, which per se presents the worst outcome of the disease, however this group is 
not representative of the range of schizophrenia. Clearly, sustaining a positive perspective 
about treatment effectiveness in this scenario is very challenging; given this negative bias it is 
difficult for clinicians to remain hopeful and focus energy and planning towards the best 
treatment strategies available for each patient.  
What opportunities for change have arisen recently? There have been significant 
advances in our understanding of schizophrenia; there is a wealth of clinical and 
neurobiological data demonstrating that schizophrenia is a neurodevelopmental disorder with 
heterogeneous phenotypes and a markedly diverse range of outcomes 4. Similarly, recent large 
cohort studies have shown that the evolution of the disease is more favourable than previously 
thought 4.  
What are the best treatment strategies for the people with schizophrenia? Although, 
the hype of neurobiological research has not yet provided a reliable set of predictors of the 
disease trajectory, there is robust evidence showing that antipsychotic medications and 
psychosocial interventions are fundamental elements in improving outcomes in schizophrenia 6. 
In order to discuss the implication for clinical attitudes, we focus on three established aspects 
of the treatment of schizophrenia that have a fundamental role in lowering rates of relapse and 
hospitalization; a) patients whose recovery is limited by poor adherence offered a trial of LAI; b) 
patients who respond poorly to first and second line antipsychotic (treatment-resistant (TR)) 
encouraged to have a trial of clozapine, and c) patients with persistent symptoms and/or social 
interactions offered adjunct psychosocial treatments 7, 8, 9, 10. All of these interventions are 
recommended in the treatment guidelines for schizophrenia, including both those of the 
American Psychiatric Association and the UK National Institute for Health and Care Excellence 
(NICE).  
Surprisingly, despite the clear advantages offered by LAI, clozapine and psychosocial 
interventions, their use remains limited  7, 8, 9, 10 . Although non-adherence reaches about 50% in 
the first year of treatment in first episode psychosis and partial adherence rates range from 
one- to two-thirds, LAI are widely underused in many settings around the world 7 . Rates of 
treatment resistance (TR) are also very high (~30%) and surveys show low rates of clozapine 
prescription ranging from 2–3% in North America to 15.9% in China and some European 
countries 8. Likewise, uptake of psychosocial treatments remains very low even though at least 
eight different evidence-based psychosocial interventions such as cognitive behavioural 
therapy, family-based services, and skills training are recommended by experts and people with 
the disorder 9.   
Why are clinicians not able to implement these evidence-based strategies that offer 
‘realistic hope’ to people with schizophrenia? Modern care delivery processes involves an 
alliance between the clinicians, the person with schizophrenia and their family and carers; this 
is a move away from paternalistic relationships towards more effective strategies, involving 
shared decision-making 1. Doctors have a key role in providing information and support in 
discussing LAI, clozapine and psychosocial interventions to empower patients and caregivers in 
their decision-making. However, there can be logistical issues with the (un)availability of both 
pharmacological and psychosocial interventions, which it is argued, may be more to do with the 
service resources than with hope, nevertheless, addressing resourcing issues also requires a 
positive attitude and hope for a positive outcome. 
The current negative perspective towards the prognosis of schizophrenia is one example 
of poor translation of current knowledge to clinical care. Without a positive attitude it is 
difficult for clinicians to maintain ‘hope’; creating a self-fulfilling prophecy, in which a false 
assessment of the situation evokes a behaviour which makes the original false conception come 
true 32. In other words, a biased view of the likely outcome in schizophrenia makes the doctors 
less hopeful towards the patients’ prognosis and thus impacts their prescribing - precluding 
patients from access to the best treatment options. Inevitably, the lack of the most appropriate 
treatment impacts on patients, resulting in poorer functioning, and hindering the recovery 
process. These poor outcomes validate the original hopeless bias, perpetuating the reign of 
error! In practice, psychiatrists end up citing this course as proof that they were right to be 
hopeless about the poor prognosis of schizophrenia from the very beginning.  
In summary, a hopeful attitude towards schizophrenia is not a naïve optimistic approach 
and needs to be able to take account of the different stages of the disease.  Since ‘hope’ is not a 
static trait, bridging the gap between contemporary advances and clinical practice should inject 
hope into the routine treatment of schizophrenia. As in current educational thinking, a growth 
mind set 10 advocating ‘realistic hope’ is essential for clinicians to provide a state-of-the-art 
clinical care for people with schizophrenia. 
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UNSTRUCTURED ABSTRACT 
According to the experience of people with schizophrenia, their psychiatrists' attitude towards 
the outcome of their illness is lacking in hope, which directly affects the mutual faith in 
treatment. Here we discuss the scientific basis of hope and show its instrumental role on 
optimizing the best treatment strategies for schizophrenia. 
PLAIN ENGLISH SUMMARY  
 
According to the experience of people with schizophrenia, their psychiatrists' attitude towards 
the outcome of their illness is lacking in hope, which directly affects the mutual faith in 
treatment. Coming from a scientific perspective, we discuss the instrumental role of the 
clinicians’ own hope for the implementation of the best treatment options. We show that the 
enlightening and restitutive power of hope is not a naïve hype approach, and should be taken in 
consideration in order to provide state-of-the-art clinical care for people with schizophrenia. 
